News
Weight loss drug Wegovy, which also goes by the name Ozempic, is responsible for slimming down celebrities such as Oprah ...
Researchers suggest people taking Ozempic and similar drugs may face double the risk of developing wet age-related macular ...
GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...
Detailed Phase IIIb STEP UP trial results presented at the 2025 ADA Scientific Sessions found that an investigational 7.2 mg dose of Wegovy (semaglutide) led to a mean weight loss of 21% in adults ...
Beyond helping diabetes patients lose weight and control blood sugar, semaglutide appears to cut dementia risk by nearly half ...
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...
Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.
MHRA is examining whether those affected have a genetic trait that is leaving them at a greater risk of side effects from the ...
At the diabetes conference, Eli Lilly presented results of a phase 1 trial of its experimental drug, eloralintide. Unlike GLP ...
Researchers found that the active ingredient in Ozempic may lower the risk of dementia in people with type 2 diabetes.
Institute of Human Anatomy - IOHA on MSN10h
Ozempic & Wegovy: How They Work and What You Need to KnowLearn about Ozempic and Wegovy, two medications making waves in weight management. Discover how they work, their benefits, ...
A blockbuster diabetes and weight-loss drug might be doing more than controlling blood sugar—it could also be protecting the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results